Susquehanna International Group
ALLO icon

Susquehanna International Group’s Allogene Therapeutics ALLO Stock Holding History

Susquehanna International Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Buy
92,100
+81,200
+745% +$163K ﹤0.01% 11467
2025
Q4 		$14.9K Sell
10,900
-4,700
-30% -$6.2K ﹤0.01% 12008
2025
Q3 		$19.3K Sell
15,600
-60,800
-80% -$72.5K ﹤0.01% 12056
2025
Q2 		$86.3K Buy
76,400
+24,700
+48% +$32.8K ﹤0.01% 11867
2025
Q1 		$75.5K Buy
51,700
+13,800
+36% +$26K ﹤0.01% 11701
2024
Q4 		$80.7K Sell
37,900
-35,600
-48% -$87.8K ﹤0.01% 11464
2024
Q3 		$206K Buy
73,500
+4,300
+6% +$11.5K ﹤0.01% 10419
2024
Q2 		$161K Buy
69,200
+38,500
+125% +$114K ﹤0.01% 10615
2024
Q1 		$137K Buy
30,700
+18,100
+144% +$75.5K ﹤0.01% 10978
2023
Q4 		$40.4K Buy
+12,600
New +$35.7K ﹤0.01% 11794
2023
Q2 		– Sell
-50,900
Closed -$251K – 11977
2023
Q1 		$251K Buy
50,900
+34,800
+216% +$223K ﹤0.01% 10106
2022
Q4 		$101K Buy
16,100
+4,000
+33% +$37K ﹤0.01% 10949
2022
Q3 		$131K Buy
12,100
+1,700
+16% +$23.1K ﹤0.01% 11413
2022
Q2 		$119K Sell
10,400
-28,300
-73% -$251K ﹤0.01% 11286
2022
Q1 		$353K Buy
38,700
+2,400
+7% +$25K ﹤0.01% 9866
2021
Q4 		$542K Sell
36,300
-105,300
-74% -$1.86M ﹤0.01% 8967
2021
Q3 		$3.64M Buy
141,600
+42,700
+43% +$1.01M ﹤0.01% 4559
2021
Q2 		$2.58M Buy
98,900
+41,700
+73% +$1.19M ﹤0.01% 5353
2021
Q1 		$2.02M Sell
57,200
-32,700
-36% -$1.1M ﹤0.01% 5896
2020
Q4 		$2.27M Buy
89,900
+1,000
+1% +$32.6K ﹤0.01% 4827
2020
Q3 		$3.35M Buy
88,900
+20,000
+29% +$754K ﹤0.01% 3678
2020
Q2 		$2.95M Buy
68,900
+23,000
+50% +$832K ﹤0.01% 3835
2020
Q1 		$892K Buy
45,900
+1,800
+4% +$42.9K ﹤0.01% 5662
2019
Q4 		$1.15M Sell
44,100
-22,200
-33% -$611K ﹤0.01% 5270
2019
Q3 		$1.81M Buy
66,300
+11,900
+22% +$339K ﹤0.01% 4415
2019
Q2 		$1.46M Sell
54,400
-21,600
-28% -$602K ﹤0.01% 4836
2019
Q1 		$2.2M Buy
+76,000
New +$2.21M ﹤0.01% 3608

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's ALLO Position: Q1 2026 in Review

Susquehanna International Group increased its Allogene Therapeutics (ALLO) stake by 39% in Q1 2026, buying an estimated $71.2K and bringing the position to 126,760 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #10791.

Susquehanna International Group first reported a position in ALLO in Q2 2019 and has held it in 27 quarters since. The position peaked at $5.45M in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Susquehanna International Group held 126,760 shares of Allogene Therapeutics worth $309K as of Q1 2026.
  • Susquehanna International Group bought 35,507 Allogene Therapeutics shares in Q1 2026, an estimated $71.2K.
  • Allogene Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10791 holding.
  • Susquehanna International Group first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Allogene Therapeutics position peaked at $5.45M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.